For individuals living with chronic conditions, stable housing enables consistent care. Conversely, housing instability can disrupt care continuity, increase financial strain, and contribute to ...

U.S. healthcare is grappling with myriad challenges: improving care and quality, managing costs, navigating new payment structures and so much more. Who is addressing these challenges and guiding ...

Capital Rx is now Judi Rx, maintaining a transparent pass-through PBM model while aligning brand architecture with the Judi ...

Two presentations found that losing Good Days copay assistance forced retina patients onto bevacizumab, worsening anatomic outcomes and visual acuity despite more frequent dosing. Researchers said ...

A retrospective study of 174,250 retina practice patients found that dismissals, though rare, disproportionately affected younger, lower-income patients with diabetic retinopathy, raising equity and ...

Preoperative statin exposure correlated with substantially reduced PVR incidence, the principal driver of rhegmatogenous retinal detachment repair failure, suggesting a potentially modifiable ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available. Fresenius Kabi has ...

Preclinical evidence positions ammonia-mediated intestinal barrier disruption as a proximal driver of MASH via gut-derived toxin influx and downstream immune activation, including hyperactive CD8+ T ...

Bevacizumab reached 29.8% of 2025 injections, rising from 23.3% in 2024, while aflibercept 2 mg fell to 21.9% from 36.9% in 2024. Reduced Good Days copay assistance disrupted affordability for branded ...

FDA authorization positions enlicitide as the first oral PCSK9 inhibitor, targeting PCSK9–LDLR interaction via macrocyclic peptide binding to deliver substantial LDL-C lowering in a daily pill ...

Retrospective Cleveland Clinic data (89 eyes) linked branded-to-bevacizumab switching with increased CST, shortened median injection interval (8.6 to 7.5 weeks), and 15.7% meeting poor-outcome ...

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD ...